Categories
All News

Latest Report on Plasma Fractionation Market by Application: Immunology, Hematology, Critical Care, Rheumatology, Pulmonology

ReportsnReports added Plasma Fractionation Market Research Report created by Report Consultant, which offers detailed insights, revenue details, and other information regarding the global market, and the various trends, drivers, restraints, opportunities, and market till 2028. Plasma Fractionation Market Report offers detailed information regarding the leading key players operating in the market, their financials, supply chain trends, technological innovations, key developments, apart from future strategies, acquisitions and mergers, and market footprint. Plasma Fractionation Market also provides a comparative analysis of the market dynamics pre and post Covid19 outbreak.

Request for FREE PDF Sample Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=320632

The global plasma fractionation market size is projected to reach USD 39.5 billion by 2025 from USD 28.6 billion in 2020, at a CAGR of 6.7% during the forecast period.

Top Company Profile Analysis in this Report

  • CSL (Australia)
  • Grifols (Spain)
  • Shire (Ireland)
  • Octapharma (Switzerland)
  • Kedrion (Italy)
  • LFB (France)
  • Biotest (Germany)
  • Sanquin (Netherlands)
  • China Biologic Products (UK)
  • Bio Products Laboratory (UK)
  • Japan Blood Products Organization (Japan)
  • Green Cross Corporation (South Korea)
  • Shanghai RAAS Blood Products (China)
  • Emergent BioSolutions (US)
  • Intas Biopharmaceuticals (India)
  • Bharat Serums and Vaccines Limited (India)
  • SK Plasma (Republic of Korea)
  • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China)
  • KabaFusion (US)
  • Centurion Pharma (Turkey)

Growth in the plasma fractionation market is primarily driven by factors such as growing use of immunoglobulins in various therapeutic areas, increase in plasma collection (and the number of plasma collection centers), rising geriatric population, and the growing prevalence of respiratory diseases and alpha-1-antitrypsin deficiency (AATD). However, the high cost of plasma products, limited reimbursements, and the emergence of recombinant alternatives are expected to restrain the growth of this market to a certain extent during the forecast period.

This report provides a detailed picture of the global plasma fractionation market. It aims at estimating the size and future growth potential of the market across different segments, such as product, application, end user, and region. The report also analyzes factors (such as drivers, restraints, and opportunities) affecting the market growth. It evaluates the opportunities in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total plasma fractionation market. The report forecasts the revenue of the market segments with respect to four major regions.

Single User License: US $ 4950
Get FLAT 25% Discount on this Report @ https://www.reportsnreports.com/purchase.aspx?name=320632

Reasons to Buy the Report:

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on plasma fractionation offered by the top 25 players in the plasma fractionation market. The report analyses the plasma fractionation market by product, application, end user, and region.
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various plasma fractionation across key geographic regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the plasma fractionation market.
  • Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players in the plasma fractionation market.

Table Of Contents in this Report-

1 Introduction
1.1 Objectives Of The Study
1.2 Market Definition
1.2.1 Inclusions And Exclusions
1.3 Scope Of The Study
1.3.1 Markets Covered
1.3.2 Years Considered For The Study
1.4 Currency
Table 1 Standard Currency Conversion Rate
1.5 Stakeholders
1.6 Summary Of Changes

2 Research Methodology
2.1 Research Approach
Figure 1 Research Design
2.1.1 Secondary Sources
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Sources
2.1.2.1 Primary Sources
2.1.2.2 Key Data From Primary Sources
Figure 2 Supply Side: Breakdown Of Primary Interviews: By Company Type, Designation, And Region
2.2 Market Size Estimation
Figure 3 Market Size Estimation: Revenue Share Analysis
Figure 4 Market Size Estimation: Plasma Fractionation Market
2.3 Market Breakdown And Data Triangulation
Figure 5 Data Triangulation Methodology
2.4 Market Share Estimation
Figure 6 Assumptions For The Study
Figure 7 Limitations Of The Study

3 Executive Summary
Figure 8 Plasma Fractionation Market, By Product, 2020 Vs. 2025 (Usd Million)
Figure 9 Plasma Fractionation Market, By Application,2020 Vs. 2025 (Usd Million)
Figure 10 Plasma Fractionation Market, By End User, 2020 Vs. 2025 (Usd Million)
Figure 11 Geographical Snapshot Of The Plasma Fractionation Market

4 Premium Insights
4.1 Plasma Fractionation Market Overview
Figure 12 Growing Use Of Immunoglobulins In Various Therapeutic Areas Is The Major Factor Driving Market Growth
4.2 North America: Plasma Fractionation Market, By Product & Country (2019)
Figure 13 Immunoglobulins Segment Accounted For The Largest Share Of The North American Plasma Fractionation Market In 2019
4.3 Plasma Fractionation Market: Geographic Growth Opportunities
Figure 14 China To Register The Highest Cagr In The Plasma Fractionation Market During The Forecast Period

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
Table 2 Plasma Fractionation Market: Impact Analysis
5.2.1 Market Drivers
5.2.1.1 Growing Use Of Immunoglobulins In Various Therapeutic Areas
Table 3 On-Label And Off-Label Indications Of Ivig
Table 4 Number Of Clinical Studies On Immunoglobulins, By Region (As Of July 2020)
Table 5 Number Of Patients Treated For Top 10 Target Conditions In The Uk
5.2.1.2 Rising Geriatric Population
Table 6 Geriatric Population, By Region, 2000?2050
5.2.1.3 Growing Prevalence Of Respiratory Diseases And Aatd
Figure 15 Global Percentage Of Deaths From Respiratory Diseases
5.2.2 Market Restraints
5.2.2.1 High Cost And Limited Reimbursement
5.2.2.2 Emergence Of Recombinant Alternatives
5.2.3 Market Opportunities
5.2.3.1 Increased Risk Of Pandemics And Communicable Diseases
5.2.3.2 Rising Prevalence Of Bleeding Disorders
Figure 16 Number Of Hemophilia A And Hemophilia B Patients Worldwide, 2012-2018
Table 7 Number Of Hemophilia Patients In Developed And Emerging Countries, 2016 Vs. 2018
5.2.4 Market Challenges
5.2.4.1 Stringent Government Regulations

6 Industry Insights

https://bisouv.com/